Nymox Pharmaceutical Corp (NASDAQ:NYMX) Short Interest Down 20.3% in July
Nymox Pharmaceutical Corp (NASDAQ:NYMX) saw a large drop in short interest in July. As of July 15th, there was short interest totalling 1,405,000 shares, a drop of 20.3% from the June 15th total of 1,763,800 shares. Based on an average daily trading volume, of 142,900 shares, the short-interest ratio is currently 9.8 days. Approximately 3.7% of the company’s stock are sold short.
NYMX stock traded up $0.02 on Friday, reaching $1.72. 36,398 shares of the company traded hands, compared to its average volume of 268,696. Nymox Pharmaceutical has a one year low of $1.25 and a one year high of $3.33. The company has a quick ratio of 8.01, a current ratio of 8.04 and a debt-to-equity ratio of 0.03. The firm’s fifty day simple moving average is $1.61.
Nymox Pharmaceutical (NASDAQ:NYMX) last posted its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter. Nymox Pharmaceutical had a negative net margin of 6,101.69% and a negative return on equity of 175.82%. The company had revenue of $0.03 million for the quarter.
Nymox Pharmaceutical Company Profile
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.